title: Statins stabilize the renal function of IgA nephropathy.
abstract: BACKGROUND
  The renoprotective pleiotropic effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has recently been reported by several investigators. However, the effect of statins on IgA nephropathy (IgAN) is still unknown.
  
  
  METHODS
  We selected 24 IgAN patients who had newly started statin therapy and were not treated with steroids and immunosuppressive agents during the observation period. We analyzed and compared clinical findings 1 year before and after treatment.
  
  
  RESULTS
  Mean age was 50.5 ± 9.91 years and mean blood pressure was 90.9 ± 10.8 mmHg. Renal function was slightly deteriorated, serum creatinine was 1.03 (0.71-1.24) mg/dL and estimated glomerular filtration rate (eGFR) was 55.8 ± 22.8 mL/min. Lipid metabolism was poorly controlled [total cholesterol 247.7 ± 35.7 mg/dL, low-density lipoprotein cholesterol 151.5 (140.8-172.8) mg/dL, and triglyceride 163.0 (126.3-243.8) mg/dL]. Mild urinary abnormality was observed [proteinuria: 0.50 (0.22-1.29) g/g creatinine, urinary red blood cells 1.0 (0.2-5.0) per high power field]. After 1 year of statin treatment, lipid control was significantly better than at baseline. Proteinuria was not significantly decreased but renal function was improved. eGFR changed from a -5.9% decrease to a 2.4% increase (p = 0.0098).
  
  
  CONCLUSIONS
  Our results indicated that statins stabilized the renal function of IgAN patients independent of their reduction of proteinuria.
authors.affiliation: Department of Medicine, Kidney Center, Tokyo Women's Medical University , Tokyo , Japan.
authors.forename: Takahito
authors.initials: T
authors.lastname: Moriyama
authors.forename: Yasuko
authors.initials: Y
authors.lastname: Oshima
authors.forename: Kayu
authors.initials: K
authors.lastname: Tanaka
authors.forename: Chihiro
authors.initials: C
authors.lastname: Iwasaki
authors.forename: Ayami
authors.initials: A
authors.lastname: Ochi
authors.forename: Mitsuyo
authors.initials: M
authors.lastname: Itabashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Takei
authors.forename: Keiko
authors.initials: K
authors.lastname: Uchida
authors.forename: Kosaku
authors.initials: K
authors.lastname: Nitta
mesh_terms: D000328:Adult; D002784:Cholesterol / Q000097:blood; D003404:Creatinine / Q000097:blood; D005260:Female; D005919:Glomerular Filtration Rate; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D006417:Hematuria / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000188:drug therapy; D012189:Retrospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides; D002784:Cholesterol; D003404:Creatinine